Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;84(5):e45-e47.
doi: 10.1016/j.jinf.2022.03.006. Epub 2022 Mar 9.

Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination

Benjamin Bonnet  1 , Hélène Chabrolles  2 , Christine Archimbaud  2 , Amélie Brebion  3 , Maud Godignon  4 , Frédéric Dutheil  5 , Céline Lambert  6 , Justine Cosme  4 , Audrey Mirand  2 , Amandine Ollier  7 , Bruno Pereira  6 , Christel Regagnon  3 , Magali Vidal  8 , Bertrand Evrard  9 , Cécile Henquell  2
Affiliations

Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination

Benjamin Bonnet et al. J Infect. 2022 May.
No abstract available

Keywords: B-cell responses; Interferon gamma (IFN-γ); SARS-CoV-2; T-cell responses; mRNA vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Authors state no conflict of interest.

Figures

Fig. 1
Fig. 1
Comparative immunogenicity of mRNA-1273, BNT162b2 and ChAdOx1 COVID-19 vaccines 3 and 6 months after vaccination Serum anti-RBD IgG antibodies and IFN-γ secreting memory T-cells via an interferon-gamma release immunoassay that uses a mix of SARS-CoV-2 spike proteins selected to activate both CD4+ and CD8+ T-cells. Box and whiskers plot indicating median and interquartile range associated with 10–90 percentile. Outliers are indicated by gray dots. One participant vaccinated with BNT162b2 withdrew during follow up, and three HCWs vaccinated with mRNA-1273 (n = 1) and ChAdOx1 / BNT162b2 (n = 2) were excluded from the M6 analysis because they developed a Delta infection between M3 and M6. BAU: binding antibody unit; IFN-γ: interferon gamma; IU: international unit; M3: 3 months after full vaccination; M6: 6 months after full vaccination; RBD: receptor-binding domain. Uninfected HCWs received two doses of vaccine. SARS-CoV-2 infected-HCWs before vaccination received one dose of vaccine.
See this image and copyright information in PMC

Comment in

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed
    1. Lopez Bernal J., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:585–594. - PMC - PubMed
    1. Thiruvengadam R., Awasthi A., Medigeshi G., Bhattacharya S., Mani S., Sivasubbu S., et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021 Available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00680..., In press. Accessed 20 December 2021. - PMC - PubMed

Publication types